Berlin, Germany
DiaMonTech AG, a breakthrough player in the Biotechnology and Health Care industries, is making strides from its headquarters in Germany. Founded in 2015, the company has garnered attention for its innovative medical device that measures blood glucose levels non-invasively. With the slogan "Say goodbye to finger pricking!", DiaMonTech leverages a patented technology utilizing an invisible infrared light beam to quantify glucose molecules, providing painless and cost-effective diabetes management.
The significant impact of DiaMonTech's technology is underscored by the global diabetes challenge, affecting over 400 million individuals worldwide. By facilitating frequent monitoring akin to the ease of unlocking a phone, the company aims to enhance ongoing diabetes management— a feature that can potentially lead to fewer diabetes-related complications.
Recently, DiaMonTech secured a Non Equity Assistance investment on 29 May 2024 from MedTech Innovator, highlighting its continued traction and potential in transforming diabetes care globally.
MELLIsim